一、本期业绩预告情况 证券代码：603590 证券简称：康辰药业 公告编号：临 2026-005 北京康辰药业股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、本期业绩预告适用于实现盈利，且净利润与上年同期相比上升 50%以上 的情形。 2、北京康辰药业股份有限公司（以下简称"公司"）预计 2025 年年度实现 归属于母公司所有者的净利润为14,500.00万元到17,500.00万元，与上年同期（法 定披露数据）相比增加 10,278.33 万元到 13,278.33 万元，同比增加 243%到 315%。 公司预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益的净利 润为 14,000.00 万元到 17,000.00 万元，与上年同期（法定披露数据）相比增加 10,892.32 万元到 13,892.32 万元，同比增加 350%到 447%。 3、本次业绩预告未经注册会计师审计。 二、上年同期经营业绩和财务状况 （一）2024 年度利润总额为 3,8 ...

南财智讯1月7日电，康辰药业发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 14,500.00万元到17,500.00万元，同比预增243.00%—315.00%；预计2025年全年归属于上市公司股东的 扣除非经常性损益的净利润为14,000.00万元到17,000.00万元，同比预增350.00%—447.00%，本期业绩 预增的主要原因：上年度，公司根据企业会计准则对收购原泰凌医药国际有限公司（现更名：方恒医药 国际有限公司)股权所形成的商誉计提商誉减值准备导致资产减值损失增加。本报告期无计提商誉减值 准备的影响。 ...

格隆汇1月7日丨康辰药业(603590.SH)公布，经财务部门初步测算，预计2025年年度实现归属于母公司 所有者的净利润为1.45亿元到1.75亿元，同比增加243%到315%。预计2025年年度实现归属于母公司所 有者的扣除非经常性损益的净利润为1.4亿元到1.7亿元，同比增加350%到447%。 本期业绩预增的主要原因：上年度，公司根据企业会计准则对收购原泰凌医药国际有限公司（现更名： 方恒医药国际有限公司）股权所形成的商誉计提商誉减值准备导致资产减值损失增加。本报告期无计提 商誉减值准备的影响 ...

Market Performance - The biopharmaceutical sector increased by 0.55% on January 6, with Liaoning Chengda leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Liaoning Chengda (600739) closed at 12.27, with a rise of 7.16% and a trading volume of 530,500 shares, amounting to a transaction value of 633 million yuan [1] - Dongbao Biological (300239) closed at 6.18, up by 5.64%, with a trading volume of 454,500 shares and a transaction value of 278 million yuan [1] - Olin Biological (616889) closed at 27.66, increasing by 3.83%, with a trading volume of 74,400 shares and a transaction value of 204 million yuan [1] - Kanghong Pharmaceutical (002773) closed at 33.75, up by 2.37%, with a trading volume of 249,700 shares and a transaction value of 838 million yuan [1] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 323 million yuan [2] - The net inflow from speculative funds was 104 million yuan [2] Detailed Capital Flow for Selected Stocks - Liaoning Chengda had a net inflow of 34.37 million yuan from institutional investors, while it faced a net outflow of 18.32 million yuan from retail investors [3] - Dongbao Biological saw a net inflow of 21.29 million yuan from institutional investors, with a net outflow of 13.16 million yuan from retail investors [3] - Tian Tan Biological (600161) had a net inflow of 18.06 million yuan from institutional investors, with a net outflow of 10.02 million yuan from retail investors [3]

Core Viewpoint - Kangchen Pharmaceutical's stock price has shown a slight increase of 2.01% this year, but has experienced a decline of 9.81% over the past 20 days and 22.69% over the past 60 days, indicating volatility in its stock performance [2]. Group 1: Stock Performance - As of January 5, Kangchen Pharmaceutical's stock price reached 40.55 CNY per share, with a trading volume of 30.14 million CNY and a turnover rate of 0.47%, resulting in a total market capitalization of 6.448 billion CNY [1]. - The stock has increased by 2.01% year-to-date, with a minor increase of 0.22% over the last five trading days, while it has seen significant declines of 9.81% over the last 20 days and 22.69% over the last 60 days [2]. Group 2: Company Overview - Kangchen Pharmaceutical, established on September 3, 2003, and listed on August 27, 2018, is located in Beijing and focuses on innovative drug research and development, integrating R&D, production, and sales [2]. - The company's main business revenue is derived from Suling (70.77%), Salmon Calcitonin (29.15%), and other sources (0.09%) [2]. - The company operates within the pharmaceutical and biotechnology sector, specifically in the sub-sector of other biological products, and is associated with concepts such as monkeypox, biopharmaceuticals, innovative drugs, venture capital, and small-cap stocks [2]. Group 3: Financial Performance - For the period from January to September 2025, Kangchen Pharmaceutical reported a revenue of 692 million CNY, reflecting a year-on-year growth of 7.10%, and a net profit attributable to shareholders of 128 million CNY, which is a 13.19% increase compared to the previous year [2]. - Since its A-share listing, the company has distributed a total of 437 million CNY in dividends, with 175 million CNY distributed over the past three years [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of shareholders for Kangchen Pharmaceutical reached 10,700, an increase of 7.18% from the previous period, with an average of 14,806 circulating shares per shareholder, a decrease of 6.12% [2]. - Notable new institutional shareholders include Qianhai Kaiyuan HuGangShen Advantage Selection Mixed A (holding 1.7445 million shares), Qianhai Kaiyuan China Scarce Asset Mixed A (holding 1.6075 million shares), and others, while several previous major shareholders have exited the top ten list [3].

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected performance that exceeds the market by more than 5% over the next six months [29]. Core Insights - The report highlights that the national government will continue to support the renewal of medical equipment in 2026, which is expected to drive demand in the medical device sector. The focus is on high-end equipment and companies with significant performance improvements and international expansion, such as Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical [3]. - The report emphasizes the optimization of application conditions and review processes for equipment renewal projects, aiming to lower investment thresholds and enhance support for small and medium-sized enterprises [3]. - The ongoing policy for equipment renewal is anticipated to sustain a favorable bidding environment for medical devices, with a gradual improvement in performance as inventory clears [3]. Summary by Sections Industry Overview - The report discusses the government's announcement on December 30, 2025, regarding large-scale equipment renewal and the inclusion of various sectors, including healthcare, in the support framework for 2026 [3]. - It outlines the measures to improve the application process for equipment renewal, including stricter requirements for equipment depreciation and minimum usage periods [3]. Investment Opportunities - The report suggests focusing on companies that are expected to show significant performance improvements and have a leading international presence in the medical device sector [3]. - Specific companies recommended for investment include Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical, which are well-positioned to benefit from the anticipated demand for high-end medical equipment [3]. Market Performance - The medical sector has experienced a decline, with a reported drop of 2.06% in the last week, ranking 25th among 28 industries [8][18]. - The report notes that the medical device market is under pressure in the short term due to policy impacts, but improvements are expected as companies innovate and expand internationally [5].

证券代码：603590 证券简称：康辰药业 公告编号：临 2026-001 北京康辰药业股份有限公司 2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 79 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 62,644,483 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 39.4952% | 注：截至本次股东大会股权登记日（2025 年 12 月 26 日），北京康辰药业股份有限公司（以 下简称"公司"）总股本 159,010,477 股，回购专用证券账户股份数为 397,400 股，因公司 所持有的本公司股份没有表决权，故此次股东大会有表决权的股份总数为 158,613,077 股。 (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 (一) 股东大会召开的时间：20 ...

北京康辰药业股份有限公司 证券代码：603590 证券简称：康辰药业 公告编号：临 2026-004 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关法律法规规定，现将公司回购股份的进展情况公告如下： 截至 2025 年 12 月 31 日，公司已累计回购股份 397,400 股，占公司总股本的 比例为 0.25%，购买的最高价为 51.40 元/股、最低价为 49.69 元/股，已支付的总 金额为 20,161,793 元。本次股份回购符合法律法规的有关规定和公司股份回购方 案的要求。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 关于股份回购进展公告 重要内容提示： | 回购方案首次披露日 | 2025/10/16，由董 ...

北京康辰药业股份有限公司 关于董事会完成换届选举及聘任高级管理人员、证券 事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603590 证券简称：康辰药业 公告编号：临 2026-003 北京康辰药业股份有限公司（以下简称"公司"）于 2025 年 12 月 31 日召开 2025 年第三次临时股东大会，会议选举产生了公司第五届董事会董事，并与公 司职工代表大会选举产生的第五届职工董事共同组成了公司第五届董事会。同日， 公司召开第五届董事会第一次会议，审议通过了《关于选举公司第五届董事会董 事长的议案》、《关于选举公司第五届董事会专门委员会委员及主任委员的议案》、 《关于聘任公司高级管理人员的议案》、《关于聘任公司证券事务代表的议案》， 现将具体情况公告如下： 一、第五届董事会及董事会专门委员会组成情况 公司第五届董事会共由 9 名董事组成，其中职工董事 1 名、独立董事 3 名。 任期自股东大会通过之日起三年。具体名单如下： 1、董事长：刘建华先生 2、董事会成员：刘建华先生、王锡娟女士、牛战旗先生 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于北京康辰药业股份有限公司 2025 年第三次临时股东大会的 法律意见书 国枫律股字[2025]A0659 号 致：北京康辰药业股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2025 年第三次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律 业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《北京康辰药业股份 有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、召 集人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出具本 ...